Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Nemtabrutinib"

2 News Found

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
Diagnostic Center | January 06, 2024

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers